A best evidence topic in cardiac surgery was written, according to a structured protocol. The question addressed was: in young patients with rheumatic aortic regurgitation compared to non-rheumatics is a Ross operation associated with increased incidence of autograft failure? The pulmonary autograft with its inherent advantages of viable autologous transplant, central laminar flow, freedom from prosthetic valve complications, side effects of anticoagulation, and growth potential is considered a well-accepted option for aortic valve replacement in young patients. However, the use of a pulmonary autograft in young patients with rheumatic aortic valve disease is controversial. We analyse existing evidence to determine the suitability of the pulmonary autograft as a substitute for the diseased aortic valve in patients with rheumatic disease. Altogether 901 papers were found using the reported search terms, from which eight represented the best evidence to answer the clinical question. In addition, a meta-analysis also superficially addressed this issue. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers are tabulated. All eight publications were from two institutions with one reporting outcomes for a Ross operation vs. mechanical valve implantation and two compared results of the Ross operation in rheumatic vs. non-rheumatic aortic valve disease. We conclude that the current available evidence suggests that pulmonary autograft is susceptible to rheumatic involvement. Use of pulmonary autograft in young patients (-30 years) with rheumatic aortic regurgitation and concomitant mitral regurgitation requires a cautious approach as there is an impaired autograft durability in this subgroup of patients.
Introduction
A best evidence topic was constructed, according to a structured protocol. This is fully described in the ICVTS w1x.
Three-part question
In wyoung patients with rheumatic aortic regurgitationx compared to non-rheumatics is wRoss operationx associated with increased incidence of wautograft failurex?
Clinical scenario
You are attending a cardiac multidisciplinary meeting. The case of a 15-year-old boy is presented, who has severe aortic and moderate mitral regurgitation (MR) due to rheumatic heart disease. The left ventricular (LV) end-systolic dimension is 56 mm and end-diastolic dimension is 77 mm. The aortic annulus measures 25 mm and the patient weighs 78.5 kg. There is a debate about the choice of surgical options for aortic valve replacement (AVR). The cardiologists are keen for a Ross operation, while the surgeons *Corresponding author. Tel.: q442074059200; fax: q442078138379. E-mail address: drrajashahzad@hotmail.com (S.G. Raja).
think that it is not a good option in view of the rheumatic aetiology. No consensus is reached and you are asked to look up the evidence on the topic and present it in the next meeting, so that a decision can be made taking into consideration the best available evidence.
Search strategy
Medline 1950 to September 2009 using OVID interface wrheumatic aortic valve diseasex AND (wRoss operationx OR wpulmonary autograftx) AND (wautograft failurex OR wreoperationx OR wreinterventionx) LIMIT to English.
Search outcome
Using the above search, 901 papers were identified for screening. Relevant papers numbered eight w2-9x of which one was a comparative study of a Ross operation vs. mechanical valve w2x and two compared results of the Ross operation in rheumatic vs. non-rheumatic aortic valve disease w4, 5x. These eight papers represented the best available evidence and are presented in full (Table 1) . In addition, a meta-analysis w10x also briefly discussed the issue of durability of pulmonary autograft in patients with rheumatic valve disease. Reoperation-free survival (nonrheumatics)s95.3"2.7% vs. Reoperation-free survival (rheumatics)s90.5"3.7%
Freedom from significant aortic stenosis or regurgitation (nonrheumatics)s91.5"2.8% vs. Freedom from significant aortic stenosis or regurgitation (nonrheumatics)s80.6"4.8% Event-free survival (nonrheumatics)s86.2"4.9% vs. Event-free survival (rheumatics)s68.9"5.3%
Probability of developing of AR was higher in young rheumatics (-30 years) with an ORs4.2, 95% CIs1.6-10.4 (Ps0.0033) 
Comment
Alsoufi et al. w2x reported the outcomes for 346 children who underwent AVR (215 underwent the Ross procedure and 131 underwent placement of a mechanical prosthesis) at their institution from 1983 to 2004. At a median followup of 6.3 years, there were 36 aortic valve reoperations: eight in patients who have received a mechanical prosthesis and 28 in patients who had a Ross procedure. In propensityadjusted analysis, the Ross procedure was strongly linked with late-phase reoperation risk (PE, 2.5"0.5; P-0.0001). Additionally, underlying rheumatic pathology was an important risk factor for late subsequent aortic valve reoperation (PE, 2.1"0.6; Ps0.0006). This effect was more apparent in patients, who underwent a Ross operation compared with those who received a mechanical prosthesis. The authors concluded that the Ross procedure confers survival advantages in the younger patients at the expense of increased reoperation risk, especially in patients with a rheumatic cause.
Sampath Kumar et al. w3x reported their experience of undertaking a Ross operation with root replacement technique in 81 rheumatic patients with aortic valve disease, mean age 29.5"11.9 years (11-56 years). Forty patients were 30 years of age or below (young rheumatics). At a mean follow-up of 92.3"40.9 months (7-132 months, median 109 months), reoperation was required in seven (8.4%) patients for autograft dysfunction with failed mitral valve repair (ns3), autograft dysfunction alone (ns2) and failed mitral valve repair alone (ns2). No reoperations were required for the pulmonary homograft. There were six (7.5%) late deaths. Actuarial survival and reoperationfree survival at 109 months were 84.5"4.1% and 90.5"3.7%, respectively. Freedom from significant aortic stenosis or regurgitation was 78.4"5.2% and event-free survival was 64.6"5.8%. When compared to rheumatics above 30 years of age, the relative risk of autograft dysfunction was high in the young rheumatics (log-ranks5.21, Ps0.022).
The same group comparing the results of a Ross operation in 153 patients with aortic valve disease (81 rheumatic and 72 non-rheumatic), with a mean age of 28"14.2 years, showed that the event-free survival at a mean follow-up of 77"42 months was 86.2"4.9% in non-rheumatics and only 68.9"5.3% in rheumatics (log-rank test, 4.23; Ps0.039) w4x. Based on these results, they concluded that the Ross procedure is not suitable for young patients (-30 years) with rheumatic heart disease. An earlier study by the same group showed similar results w6x.
Pieters et al. w5x in a comparative study of 144 patients (119 rheumatic, 25 non-rheumatic) showed that the autograft reoperation incidence was 22% (26y119) in rheumatic patients vs. 8% (2y25) in non-rheumatic patients (PsNS). Preoperative predictors for reoperation in the rheumatic group were severe concomitant MR, followed by male gender and large indexed LV outflow tract (all P-0.001 by discriminant analysis). Three earlier publications by the same group w7-9x also suggested that although the Ross procedure remains a safe and attractive alternative in aortic valve operation, the progression of aortic regurgitation, especially in the younger patient with rheumatic aetiology, remains a concern.
A recently published meta-analysis and systematic review of reports published from January 2000 to January 2008 on outcome after the Ross procedure also suggested that there was an association between rheumatic valve disease in young patients and increased autograft dysfunction w10x.
Limitations
The available evidence is weak and predominantly from case series. Majority of the studies report clinical and echocardiographic outcomes with short-to mid-term follow-up. Assessment of functional outcomes using cardiopulmonary exercise testing and modern imaging modalities w11x will shed further light on this subject.
Conclusion
The available evidence suggests that the Ross procedure confers survival advantages over mechanical valve in young patients with rheumatic aortic valve disease. However, use of pulmonary autograft in younger patients (-30 years) with rheumatic aortic regurgitation and concomitant MR requires a cautious approach as there is an impaired autograft durability in this subgroup of patients with increased incidence of autograft failure requiring reoperation.
